Cinamycin300 mg/2 ml

Cinamycin is a lincosamide antibiotic used to treat infections caused by susceptible anaerobic bacteria and certain gram-positive aerobic bacteria. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Serious lower respiratory tract infections (e.g., empyema, anaerobic pneumonitis, lung abscess)
• Skin and soft tissue infections
• Bone and joint infections, including osteomyelitis
• Gynecologic infections (e.g., endometritis, pelvic inflammatory disease), typically as part of combination therapy
• Intra-abdominal infections, typically combined with an agent active against gram-negative aerobes
• Septicemia caused by susceptible organisms

Guideline-supported / adjunct uses

• Alternative agent for dental and certain procedural infective-endocarditis prophylaxis in patients with a true penicillin allergy
• Component of combination regimens for necrotizing skin/soft-tissue infections, for its anti-toxin effect against toxin-producing organisms such as Group A Streptococcus

Off-label uses (physician discretion, in combination with other agents)

• Adjunct treatment of severe toxoplasmosis or Pneumocystis jirovecii pneumonia in patients intolerant of first-line therapy
• Adjunct treatment of certain malaria cases in combination with quinine

Cinamycin is not effective for meningitis because it does not adequately cross the blood-brain barrier, and it should not be used for non-bacterial infections such as the common cold.

Clindamycin [Oral/Injection] is available as clindamycin hydrochloride capsules for oral use (commonly 75 mg, 150 mg, and 300 mg strengths) and as clindamycin phosphate solution for injection (commonly equivalent to 150 mg/mL of clindamycin base, supplied in ampoules/vials for intravenous or intramuscular administration).

Cinamycin is a semi-synthetic lincosamide antibiotic derived from lincomycin. It is active against many anaerobic bacteria and a range of gram-positive aerobic cocci. It is available in both oral (capsule) and injectable (IV/IM) formulations, allowing flexible use across mild-to-severe infections, including step-down therapy from injectable to oral administration as a patient improves.

Lincosamide antibiotic

Clindamycin [Oral/Injection] inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation. Depending on the organism, drug concentration, and site of infection, its action may be bacteriostatic or bactericidal. It has no clinically useful activity against most gram-negative aerobic bacteria.

After oral administration, clindamycin hydrochloride is well absorbed, and absorption is not significantly affected by food. After intramuscular or intravenous administration, the clindamycin phosphate prodrug is rapidly hydrolyzed to active clindamycin. The drug distributes widely into most body tissues and fluids, including bone, but does not achieve therapeutic concentrations in cerebrospinal fluid. It is metabolized in the liver and excreted primarily via bile and urine.

Oral capsules should be swallowed whole with a full glass of water and may be taken with or without food; avoid lying down immediately after a dose. Injectable Cinamycin (clindamycin phosphate) must be diluted and administered by slow intravenous infusion over at least 10–60 minutes (not exceeding 30 mg/minute) or by deep intramuscular injection of no more than 600 mg per injection site; it must not be given as a rapid intravenous bolus.

Cinamycin has the following well-documented, clinically significant interactions:

• Neuromuscular blocking agents (e.g., vecuronium, rocuronium): Cinamycin has intrinsic neuromuscular blocking activity and may enhance the action of these agents, increasing the risk of prolonged respiratory depression/paralysis; use with caution during anesthesia.
• Strong CYP3A4/CYP3A5 inhibitors (e.g., certain azole antifungals, macrolides): may increase clindamycin plasma concentrations; monitor for adverse effects.
• CYP3A4/CYP3A5 inducers (e.g., rifampin): may reduce clindamycin efficacy; monitor clinical response.
• Erythromycin: antagonistic in vitro and may induce resistance; concurrent use is generally avoided.
• Anti-diarrheal/anti-peristaltic agents (e.g., loperamide): may worsen or prolong C. difficile-associated diarrhea if it occurs and should generally be avoided if diarrhea develops during treatment.

Common side effects of Cinamycin include:

• Gastrointestinal: abdominal pain, nausea, vomiting, diarrhea, esophageal irritation/ulceration (oral capsules), metallic taste
• Skin: rash, pruritus, urticaria
• Injection-site reactions: pain, induration, thrombophlebitis (IV), local abscess (IM)

Less common but serious effects include severe hypersensitivity reactions (including anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis), hepatotoxicity, and Clostridioides difficile-associated diarrhea/colitis — see Precautions and Warnings for full details and warning signs that require urgent medical attention.

Pregnancy: Available human data have not shown an increased risk of major birth defects when Cinamycin is used in the second or third trimester; data on first-trimester use are more limited. As with any medicine in pregnancy, Cinamycin should be used only if clearly needed and if the potential benefit justifies the potential risk to the fetus; always consult a physician before use in pregnancy.

Lactation: Clindamycin passes into breast milk. Breastfed infants should be monitored for possible effects on the gastrointestinal flora, such as diarrhea or candidiasis. A physician should weigh the benefits of breastfeeding against the mother's need for Cinamycin and any potential effects on the infant.

Clostridioides difficile-associated diarrhea (CDAD)

Cinamycin, like nearly all antibacterial agents, has been associated with Clostridioides difficile-associated diarrhea (CDAD), ranging in severity from mild diarrhea to fatal pseudomembranous colitis. CDAD can occur during treatment or as late as several weeks after the last dose. Seek prompt medical attention for severe, persistent, or bloody diarrhea, or abdominal cramping/fever occurring during or after treatment, as this may require discontinuing Cinamycin and starting specific antimicrobial therapy directed against C. difficile.

Hypersensitivity reactions

Severe hypersensitivity reactions, including anaphylaxis and severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms), have been reported. Discontinue Cinamycin immediately if a hypersensitivity or severe skin reaction occurs and seek medical attention.

Hepatic and renal effects

Hepatotoxicity (rarely including jaundice and abnormal liver function tests) has been reported; periodic liver and kidney function tests are recommended during prolonged therapy or in patients with hepatic/renal impairment. Cases of acute kidney injury have also been reported.

Other precautions

• Use with caution in patients with a history of gastrointestinal disease, particularly colitis.
• Elderly patients may tolerate severe diarrhea less well and should be monitored closely.
• Cinamycin is not effective for meningitis due to poor CNS penetration and should not be used for it.

Antibiotic stewardship: Take Cinamycin exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

There is no specific antidote for Cinamycin overdose, and hemodialysis and peritoneal dialysis are not effective in removing the drug from the blood. If an overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze the injection solution.

Renal impairment

No dosage adjustment is generally required in renal impairment, since Cinamycin is largely metabolized hepatically; however, caution and monitoring are advised in severe renal impairment (see Precautions and Warnings).

Hepatic impairment

Use with caution; consider dose adjustment or extended dosing intervals in severe hepatic impairment, and monitor liver function during prolonged use.

Elderly

No specific dose adjustment is required based on age alone, but elderly patients may be more susceptible to severe diarrhea/CDAD (see Precautions and Warnings) and should be monitored closely.

Pregnancy and lactation

See Pregnancy and Lactation section.

Pediatric use

See Pediatric Uses section.

The duration of treatment with Cinamycin depends on the type and severity of infection and is determined by the prescribing physician; typical courses range from 7 to 14 days, though certain infections (e.g., bone and joint infections) may require several weeks of therapy. Patients should complete the full prescribed course even if symptoms improve early, to reduce the risk of relapse and antibiotic resistance.

Lincosamides

Clindamycin [Oral/Injection] binds reversibly to the 23S ribosomal RNA of the 50S ribosomal subunit of susceptible bacteria, inhibiting bacterial protein synthesis by blocking peptide bond formation and interfering with translocation of peptidyl-tRNA. This action is bacteriostatic or bactericidal depending on the organism and the drug concentration achieved at the site of infection.

B

Cinamycin may be used in pediatric patients, including neonates, with dosing based on age and body weight:

• Neonates (younger than 1 month): 15–20 mg/kg/day IV/IM in 3–4 equally divided doses.
• Infants and children 1 month to 16 years: 20–40 mg/kg/day IV/IM in 3–4 equally divided doses for serious infections, or approximately 8–25 mg/kg/day orally in 3–4 divided doses depending on severity of infection.

Safety and efficacy of specific dosing regimens have not been established for all pediatric age groups and indications; pediatric dosing of Cinamycin should always be individualized and supervised by a physician.